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Background: Berberis vulgaris is a well known plant with traditional herbal medical history. The aims of this study
was to bioscreen and compare the in vitro biological activity (antioxidant, cholinergic, antidaibetic and the
anticancer) of barberry crude extract and berberine active compound.
Methods: The effect of B. vulgaris extract and berberine chloride on cellular thiobarbituric acid reactive species
(TBARS) formation, diphenyle–α-picrylhydrazyl (DPPH) oxidation, cellular nitric oxide (NO) radical scavenging
capability, superoxide dismutase (SOD), glutathione peroxidase (GPx), acetylcholinesterase (AChE) and α-gulcosidase
activities were spectrophotometrically determined. On the other hand, the effect of extract and berberine as
anticancer was estimated on three different cell lines which were MCF-7, HepG-2, and Caco-2 cells by using neutral
red uptake assay which compared with control normal cells (PBMC).
Results: Our results showed that barberry crude extract contains 0.6 mg berberine/mg crude extract. Barberry
extract showed potent antioxidative capacity through decreasing TBARS, NO and the oxidation of DPPH that
associated with GPx and SOD hyperactivation. Inhibitory effect of berberis crude extract on α-glucosidase was more
potent than that of berberine chloride, while both had the same AChE inhibitory effect. Besides, different
concentrations of both berberine chloride and barberry ethanolic extract showed to have no growth inhibitory
effect on normal blood cells (PBMC). Otherwise, both berberine chloride and barberry ethanolic extract showed to
have inhibitory effect on the growth of breast, liver and colon cancer cell lines (MCF7, HepG2 and CACO-2,
respectively) at different incubation times starting from 24 hrs up to 72 hrs and the inhibitory effect increased with
time in a dose dependant manner.
Conclusion: This work demonstrates the potential of the barberry crude extract and its active alkaloid, berberine,
on suppressing lipid peroxidation, suggesting a promising use in the treatment of hepatic oxidative stress,
Alzheimer and idiopathic male factor infertility. Beside, berberis vulgaris ethanolic extract is safe non-toxic extract as
it was not inhibit the growth of PBMC that can induce cancer cell death that could return to its powerful
antioxidant activity.
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Table 1 Compounds isolated from berberis vulgaris
Compound Nature Compound Nature
Aromoline Alkaloid Oxyberberine Alkaloid
Berbamine Alkaloid Oxycanthine Alkaloid
Berberine Alkaloid Palmatine Alkaloid
Berlambine Alkaloid Quercentin Flavonoid
Bervulcinc Alkaloid Rutin Flavonoid
Columbamine Alkaloid (-)-tejedine Alkaloid
Hydroxycanthine Alkaloid Yatronizine Alkaloid
Isocorydine Alkaloid
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As it is increasingly believed now that traditional medicines
become more popular worldwide, there is accumulating
evidence suggesting medicinal plants are unlimited reser-
voirs of drugs. The amazing structural diversity among their
active components makes them a useful source of novel
therapeutics. Researchers with interest in natural products
have intensified their efforts towards scientific evaluation of
traditional medicines. The World Health Organization
(WHO) estimates that herbal medicine is still the most
common source for primary health care of about 75-80% of
the world's population, mainly in the developing countries,
because of better cultural acceptability, better compatibility
with the human body and fewer side effects [1].
Berberis vulgaris is a shrub in the family Berberidaceae,
native to central and southern Europe, northwest Africa
and western Asia. It grows in a variety of soils, though
is primarily cultivated in cooler regions [2-4]. Its fruit is
an oblong red berry 7–10 mm long and 3–5 mm broad,
ripening in late summer or autumn; it is edible but very
sour, and rich in vitamin C. Barberry is extensively used
as food additive and its juice is recommended to cure
cholecytitis [5].
Barberry has a long history of use in traditional eastern
and western herbalism [6].
Berberis vulgaris as well as other berberine (BER)
containing plants [7] are used medicinally in virtually
all-traditional medical systems, and have a history of
usage in Ayurvedic, Iranian and Chinese medicine dating
back at least 3,000 years [8]. Ancient Egyptians used
barberry fruit with fennel seeds to ward off pestilent
fevers [6]. Indian ayurvedic physicians used barberry in
the treatment of dysentery and traditional Iranian medi-
cine uses its fruit as a sedative [6,9]. In northern Europe
barberry was used to treat gall bladder and liver prob-
lems, while it was used in the treatment of abnormal
uterine bleeds and rheumatism in Russia and Bulgaria
[10,11]. In North America, the Eclectics used barberry
for treatment of malaria and as a general tonic [12].
Also, the American Indians found it effective in improv-
ing appetite and used its dried fruit as a gargle [13,14].
Phytochemical analysis of root, stem or bark extract of B.
vulgaris demonstrated the presence of protoberberines and
bisbenzyl-isoquinoline alkaloids (berbamine, tetrandrine
and chondocurine, (Table 1) for which anti-inflammatory
and immuno-suppressive activities have also been well
established [15]. Medicinal properties for all parts of
the plant have been reported, including tonic, anti-
microbial, antiemetic, antipyretic, antipruritic, antioxidant,
anti-inflammatory, hypotensive, antiarrhythmic, sedative,
antinociceptive, anticholinergic and cholagogue actions,
and it has been used in some cases like cholecystitis, chole-
lithiasis, jaundice, dysentery, leishmaniasis, malaria and gall
stones [16] (Table 2). Furthermore, BER, an isoquinolinealkaloid and the major ingredient of this plant, has been
used for treating diarrhea and gasterointestinal disorders
for a long time [17,18]. It has multiple pharmacological ef-
fects including; antimicrobial activity against 54 microor-
ganisms [19-21], inhibition of intestinal ion secretion and
smooth muscle contraction, inhibition of ventricular tachy-
arrhythmia, reduction of inflammation, stimulation of bile
secretion and bilirubin discharge [22]. In spite of extensive
applications and numerous properties, the mechanism of
action in most of its effects is not exactly clear. Some of
these properties may occur due to antihistaminic and anti-
cholinergic effects.
Among berberine multiple pharmacological actions,
anti-inflammatory activity has been extensively studied
[23]. Antipyretic activity of berberine sulfate has also been
shown by Sabir and Bhide 1971 using a model of experi-
mentally induced fever in rats [22]. This effect has been
found to be approximately three times greater than so-
dium salicylate. Anti-colitic property is another pharma-
cological effect has been demonstrated for berberine by
Zhou and Mineshita [24].
The barberry phenolic compounds include anthocyanins
and carotenoid pigments [22-26]. Several pharmacological
effects such as antioxidant and cytoprotective [27], inhibi-
tory effects on capillary permeability [28] and epidermal
growth factor [29] anticholinergic and antihistaminergic
[27], have been demonstrated for anthocyanins and
berberry fruit extract (BFE).
The aim of this study was to compare the in vitro bio-
logical activity (antioxidant, cholinergic, antidaibetic and
the anticancer) of barberry crude extract and berberine
active compound.Methods
Human and animal biological samples
Human participants and their biological materials (blood)
met the ethical standards for donor approval required by
national regulatory bodies. Blood samples were collected
from ten healthy subjects after they signed consent
Table 2 The pharmacological effects of Berberis vulgaris (NAPALERT; natural products alert database)
System Effect Part of plant Preparation
Cardiovascular Hypotensive activity Dried root Alkaloid fraction
Dried fruit Aqueous extract
Gastrointestinal Gastric secretory stimulation Root Ethanol—H20 (67%) extract
Endocrine Choleretic activity in rat Dried root Total alkaloids
Choleretic activity Stem bark
Increases tone of the digestive tract and gives rise to increased
and irregular peristalsis
Dried root
Anticholinergic activity in guinea pig ileum Dried fruit Decoction
Menstruation induction effect in guinea pig Stem Ethanol (95%) extract
Uterine stimulant effect in cat, rabbit and guinea-pig Leaf Ethanol-acetone (50%) extract
Immune system Antibody formation suppression in mouse Dried root Alkaloid fraction
Antiinflammatory activity Root Alkaloid fraction
Organisms Complement alternative pathway inhibition Root Ethanol (l00%) extract




Antipyretic activity in rat Dried bark Alkaloid fraction
Dried fruit Ethanol (95%) extract
Narcotic antagonist activity Dried root
Sedative Fruit
Renal Diuretic activity in rat Dried bark Alkaloid fraction
Other Toxicity assessment in mouse— LD50 = 520 0 mg/kg Dried root Alkaloid fraction
Toxicity assessment in mouse— LD50 = 2.6 ± 022 g/kg b w
Male
reproduction
Idiopathic ma factors due to oxidative damage Root Crude methanolic (95%) extraction
Crude acetic acid (5%) extraction
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approval and all study protocols for animal and biological
tissue samples treatment, involved in this study, were firmly
subjected to ethical instructions outlined by Animal Ethics
Committees (AEC) that published via The National Health
and Medical Research Council (NHMRC) policies and
guidelines that recommended by the Egyptian Ministry of
Health and Population, High Committee Of Medical Spe-
cialties, Arab Republic of Egypt [30]. This study was
permission granted from the Biomedical technology,
SRAT-city and Biochemistry Department, Faculty of
Science, Alexandria University, following approval of the
Research Ethics Committee, Faculty of Pharmacy, Alexan-
dria University.Barberry, Berberis vulgaris
Barberry’s roots were purchased and authenticated by
Prof. Salma El-dareir, Botany Department, Faculty of
Science, Alexandria University, Egypt. Firstly, this classi-
fication was being dependent on the data about the
plant published in Dargon Herbarium [31]. Afterclassification, the plant roots were separated then dried
at room temperature, powdered, sieved, and stored
prior to further use. Dried barberry roots were phyto-
chemically screened for alkaloids, phobatannins,
saponnins, flavonoids, steroids, terpenoids and cardiac
glycosides [1].Barberry crude extract preparation
The dried powdery roots of barberry were exhaustively
defatted with petroleum ether then dried in fresh air to
evaporate the solvent. The dried roots were used to pre-
pare the ethanolic crude extract by subjecting to steam
distillation method using Soxhlet apparatus in which the
powder was added in glass thimble and boiled ethanol
extracted the active compounds for 8 hours. The ethanolic
extract was concentrated to minimum volume using ro-
tary evaporator at 60°C and 100 rpm (Büchi, Switzerland)
then lyophilized (DISHI, DS-FD-SH10, Xi’an Heb Biotech-
nology Co, China) to obtain a powder extract of barberry
(25%). The barberry extract powder form was kept at −20°
C until subjected to further biochemical analysis.
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The ethanolic extract was analyzed using HPLC (Series 500
Bio-Tek Instrument, Milano, Italy) to determine the berber-
ine concentration in the extract. The analytes were sepa-
rated by a Zorbax Eclipse XDB-C18 (250 × 4.6 mm i.d.,
5 μm particle size) column (Agilent, Santa Clara, CA,
USA).
The freeze-dried Berberis vulgaris extracts were
dissolved in equal volume water: ethanol solution (1 mg/
ml) and were filtered through a 0.22-μm syringe filter
prior to HPLC analysis. The operating temperature was
maintained at 30°C and the detector was operated at a
wavelength of 254 nm. The mobile phase was a mixture
of two solvent compositions, solvent A (deionized water)
and solvent B (methanol). The program was started with
40% solvent A and 60% solvent B at a solvent flow of
0.8 ml/min and injection volume of 20 μl [32].
Preparation of berberine chloride
Berberine chloride was commercially available from
Sigma-Aldrich where, different concentrations of berber-
ine chloride were prepared by dissolved certain weights
at 1 ml of 10% ethanol.
Preparation of liver homogenate
Six Balb/c mice were obtained from animal of house of
medical research institute, Alexandria University. After
anesthesia, liver was isolated and washed in cold saline,
and then one gram of each liver was homogenized in
9 mL phosphate buffer saline. The homogenate was
centrifuged at 3000 and metabolites containing super-
natant was decanted for further biochemical estimations.
Biochemical assays
1. Determination of Acetylcholinesterase (AChE) activity
AChE activity was measured according to the
method of Ellman et al. [33]. 130 μL phosphate
buffer (0.1 M pH 7.4) were added to a mixture of
20 μL of liver homogenate and 20 μL of barberry
extract (test) or organic solvent (control), then
incubated for 45 min at 37°C. 5 μL of substrate
ACTI (75 mM) were added, mixed well and
incubated for 15 min at 37°C. 60 μL DTNB
(0.32 mM) were added and left for 5 min. The
absorbance was measured at 405 nm and the
specific activity was calculated.2. Determination of α-glucosidase activity
Method mentioned by Han and Srinivasan [34] was
carried out with a slight modification to estimate the
effect of barberry extract on α-glucosidase (EC
3.2.1.20) activity. 100 μL of barberry extract (test),
organic solvents (control) or dH2O (blank) were
diluted with 2.5 mL of 0.1 M phosphate buffer,pH 7.4. 100 μL of liver homogenate were added,
mixed well and incubated in a water bath with the
reaction mixture at 30°C for 5 min. 500 μL PNPG,
5 mM, were added and the reaction was allowed to
proceed for 15 min. The reaction was stopped by the
addition of 2 mL of 1 M Na2CO3. The producing
color was spectrophotometrically detected at 400 nm.
A unit of enzyme activity was defined as nmoles of
p-nitrophenol released/min.3. Determination of Thiobarbaturic acid reactive substance
(TBARS) level in induced lipid peroxidation model
Two mL of barberry extract or berberine chloride
(test), the organic solvent (control) or distilled
water (dH2O) (blank) were incubated with equal
volume of liver homogenate for about 45 min at
37°C. In vitro tissue lipid peroxidation was induced
by adding H2O2 and ferrous sulphate (FeSO4.7H2O)
at a final concentration of 1 mM and 0.5 mM,
respectively, in both test and control reaction
mixtures. After an incubation period of about
30 min at 37°C, butylated hydroxyl toluene (BHT)
was added at a final concentration of 0.02% and
mixed carefully to stop the peroxidation reaction.
The mixtures were centrifuged at 3000 rpm for
15 min, and then 1 mL of the resultant supernatant
was mixed with 1 mL of 15 % trichloroacetic acid
(TCA) followed by centrifugation at 3000 rpm for
10 min [1].
Then TBARS was determined in previous solution
according to the method described by Wills [35].
1 mL of protein free supernatant was mixed with
500 μL of 0.7% thiobarbituric acid (TBA), heated in
boiling water bath for 45 min, cooled and the
colour in the supernatant was detected at 532 nm.
The TBARS level was calculated against a control
according to the following equation: TBARS level
(nmol/ml) = At / 0.1564. Determination of Diphenyle –α-picrylhydrazyl (DPPH)
radical scavenging
%scavenging ¼ A control−A sampleð =A control  100½
DPPH radical scavenging assay of the total extract
was performed by using the previously established
and modified methodology by Choi et al. [36]. Assays
were performed in flat bottom polystyrene 96 well
microtiter plates. To 100 μL of each sample (1-6 mg/
ml) in EtOH 25 μL DPPH (1 mM) in ethanol was
added. The resultant mixture was briefly shaken and
maintained at room temperature, in the dark for
30 min. At the end of this period, the absorbance (A)
of the mixture was measured at 490 nm, using
ELISA. Scavenging ratio of DPPH assay calculated as
follows:
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NO scavenged ¼ A control−A testð Þ=A control½   100
Nitric oxide was determined by the method
described by Green et al. [37], where nitric oxide
was generated from sodium nitroprusside and
measured by Griess reaction. Scavenger of nitric
oxide competes with oxygen leading to reduced
production of nitric oxide. Sodium nitroprusside
(5 mM) in phosphate buffered saline (pH 7.2),
was mixed with different concentrations (1–6 mg/ mL)
of the extract and incubated at 25°C. Samples
from the above were reacted with Griess reagent
(1% sulphanilamide, 2% phosphoric acids and 0.1%
Naphthylethylendiamine hydrochloride). The
absorbance of the chromophore (A) formed
during the diazotization of nitrite with
sulphanilamide and subsequent coupling with
naphthylethylenediamine was read at 546 nm.
The scavenged ratio of NO calculated as follows:6. Determination of SOD activity
Twenty microliters of liver homogenate supernatant
(test) or buffer (reference) and 20 μl of extract or
berberine chloride different concentrations were
added to 1 mL buffer solution and incubated at
37°C for 45 min. 10 μl pyrogallol (20 mM in HCl,
10 mM) was added to the previous solution and the
absorbance of test (At) or reference (Ar) was
measured at 420 nm against air after 30 and 90 s.
The percentage inhibition of pyrogallol autoxidation
by supernatant was calculated according to the
following equation:
The percentage inhibition
¼ 100–½ At=min=ml sampleð Þ=
Ar=min=ml referenceð Þ  100
The specific activity of serum SOD as ng/min/mg
protein was calculated with dividing the value of
SOD in ng/min/ml by protein concentration in
the sample.
One unit of SOD activity is defined as the amount
of enzyme which inhibits the rate of auto-oxidation
of pyrogallol by 50%. From the standard curve it
was found that, one unit equals 153 ng. The sample
enzyme activity in U/ mg protein was obtained by
diving value in ng/ min/ mg protein by 153 [38].7. Determination of liver glutathione peroxidase
(GPx) activity
Fifty microliters of liver homogenate were
incubated with equal volume of different extract
or berberine chloride different concentrations for
45 min at 37°C, then were added to 100 μl GSH,
100 μl cummen H2O2 and 750 μl Tris–HCl,pH 7.6 (test) and incubated at 37°C for 10 min.
For control, 50 μl diluted supernatant and100 μl
GSH were added to 750 μl Tris–HCl, pH 7.6,
then incubated at 37°C for 10 min. One milliliter
TCA was added to test and control as well as
100 μl cummen H2O2 were added to control
then both were centrifuged at 3000 r.p.m. for
20 min and then the supernatants were separated
off. One milliliter of supernatants was added to
2 ml Tris–HCl, pH 8.9 and 100 μl DTNB then
incubated for 5 min [39]. The absorbances of test
and control (Ac) were read at 412 nm against
distilled water. The activity of liver GPx was
calculated with the following equation;
GPx activity U=g wet tissueð Þ
¼ E  6:2 10 10=13:1 0:05 10In Vitro anticancer assay
In order to determine the safe concentrations of both bar-
berry ethanolic extract and berberine standard that can be
used for In Vitro cell culture; normal peripheral blood
mononuclear cells (PBMC) were isolated from a healthy
individual by Ficoll-Hypaque (density 1.077 g/L, Lonza,
USA) gradient centrifugation. PBMC were collected and
washed using HBSS, then cell viability and count were
determined using Trypan blue exclusion test. After
collecting the PBMC, cells were suspended at concentra-
tion of 1×106 cell/ml in RPMI 1640 (Lonza) 25 mMN-2-
hydroxyethylpiperazine-N`-2-ethanesulfonic acid (HEPES)
(Lonza), 4 mM L-glutamine (Lonza), 100U of penicillin
and 100 μg streptomycin (Lonza) and 10% FBS (Lonza).
In 96 well plate, 1×105 cell/well were seeded with different
concentrations ranging from 0 to 100 μg/ml (20, 40, 60,
80, 100 μg/ml) of barberry ethanolic extract, or berberine
standard for 72 hr at 37°C incubator with 95% humidity
and 5% CO2.
The cytotoxic effect of the different concentrations of
the extract and the standard were determined using the
neutral red uptake assay [40]. Briefly, Neutral red work-
ing solution (80 μg/ml) (Serva, Austria) was incubated
overnight at 37°C. In each well of the incubated cells,
culture media was removed and 100 μl of neutral red
medium were added then incubated for 3 hr to allow for
vital dye incorporation into living cells. The neutral red
media was removed and rapid rinsed with 150 μl HBSS.
Dye was extracted from the cells by adding 150 μl ex-
traction buffer (1% acetic acid: 50% ethanol (96%): 49%
deionized H2O) followed by rapid agitation for at least
10 min on micrometer plate shaker. The extract neutral
red color intensity was measured at 490 nm in a micro-
titer plate reader spectrophotometer.
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neutral red intensity value, IC50 of the barberry ethanolic
extract and standard berberine chloride was calculated.
Following the same method selected concentrations of
both barberry ethanolic extract and standard berberine
chloride were used to examine their effect on different
cancer cell lines. In a 96-well tissue culture plates, MCF-
7, HepG-2, Caco-2 and EL4 cells were plated each in its
respective culture media, at a density of 3000 cells/well,
11000 cells/well, 6000 cell/well and 15000 cells/well, re-
spectively. Cells were left to adhere by incubation for
24 hr at 37°C, 95% humidity and 5% CO2. Following that
the selected concentration of the ethanolic extract or
standard was added and cell viability was measure at
24 hr intervals for maximum of 72 hr using neutral red
uptake assay as previously described.Statistical analysis
All data are expressed as the mean ± standard deviation
(SD). The differences were considered to be statistically sig-
nificant at P < 0.05. Statistical analyses were performed using
Primer of Biostatistics program V5 for analysis of the un-
paired Student's t-test and one-way analysis of variation
(ANOVA).Results
Preliminary phytochemical screening of barberry’s roots
revealed the presence of alkaloids, flavonoids, saponin,
phenolic contents, terpenoids and cardiac glycosides.
However, steroid and phobatannins were not detected.
The percentage of alkaloids, flavonoids, saponin and
total phenolic content were 4, 1.9, 0.35 g/ 100 gm plant
tissue and 100 mg/ml of ethanolic extract, respectively
(Table 3). Table 3 and Figure 1 showed that 1 mg of ber-
beris ethanolic extract contains 0.6 mg berberine active
compound.
Figure 2 showed that Berberis vulgaris and berberine
chloride different concentrations exerted the same AChE
inhibitory ability in percentage (%) at p < 0.05, this in-
hibitory effect was increased as the concentration of Ber-
beris vulgaris and berberine chloride increased.
Both Berberis vulgaris and berberine chloride had α-
glucosidase inhibitory effect but the effect of Berberis
crude extract was more potent than that of berberine
chloride as shown in Figure 3. Furthermore, this inhibi-
tory effect was directly proportional with that ingredient
concentration at p < 0.05.Table 3 Quantitative phytochemical screening of
barberry roots and Berberine concentration in Berberis
vulgaris crude extract
Extract Berberice concentration (mg/mg extract)
Ethanolic extract 0.62The antioxidants effect of Berberis vulgaris crude ex-
tract and berberine chloride were tabulated in Table 4.
Our results showed that both crude extract and active
ingredient had powerful antioxidants properties as they
inhibited the production of TBARS, NO and the oxida-
tion of DPPH that associated with GPx and SOD
hyperactivation. These biochemical properties were
exerted in a concentration dependent manner where
TBARS production decreased from 9 ± 0.3 nmol/g to
4 ± 1.1 nmol/g as the concentration of berberis crude ex-
tract increased from 0.2 mg/ml to 1 mg/ml. The same
pattern and the same inhibitory effect were shown with
berberine chloride different concentrations. Both ber-
beris extract and berberine chloride different concentra-
tions ranged from 0.2-1 mg/ml lowered NO level in
range from 16 to 25%, respectively, at p < 0.05. Further-
more, the same tested concentrations of B. vulgaris or
berberine chloride inhibited the DPPH oxidation in
range from 13 to 46% than control level at p < 0.05. On
the other hand, the GPx and SOD activities increased in
the range of 10-70% and 55-270%, respectively, when the
concentration of Berberis vulgaris or berberine chloride
increased from 0.2 mg/ml to 1 mg/ml as comparing with
control levels.
The cytotoxicity study that was done on PBMC for
both of b. vulgaris extract and berberine chloride, the
main alkaloid constituent, showed that both of them had
not any mentioned cellular toxicity while they had a sig-
nificant proliferatory effect. As, different concentrations
(20, 40, 60, 80 and 100 μg/ml) of both berberine chloride
and barberry ethanolic extract showed to have inhibitory
effect on normal blood cells (PBMC) growth rate main-
tenance, in contrary they slightly stimulated the prolifer-
ation of PBMC (Figure 4) especially after incubation for
72 hrs. At the same time as indicated in Figure 5, con-
centrations starting from 1 μg/ml up to 100 μg/ml of
both berberine chloride and barberry ethanolic extract
showed to have inhibitory effect on the growth of breast,
liver and colon cancer cell lines (MCF7, HepG2 and
CACO-2, respectively) at different incubation times
starting from 24 hrs up to 72 hrs and the inhibitory ef-
fect increased with time in a dose dependant manner. It
was interest to notice that with time the inhibitory dose
of both berberine chloride and barberry ethanolic extract
increased with time in case of normal cells (PBMC) and
decreased dramatically with time in case of cancer cells
(Table 5).
Discussion
The phytochemical constituents of B. vulgaris act in syn-
ergism to increase barberry's bioactivity such as antioxi-
dant, antimicrobial, anticholinergic, anti-diabetic, etc.
[41]. In our previously published work, we mentioned
that B. vulgaris ethanolic extract has a competitive
Figure 1 Berberis vulgaris ethanolic extract HPLC chart.
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over activity of AChE in dementia patients [42]. In
agreement with this finding, our data showed the same
inhibitory effect toward AChE enzyme. This inhibitory
effect may be returned to the presence of berberine in
ethanolic crude extract where it represented 60% of its
ingredients. Berberine binds AChE active site as it is acts
as competitive inhibitor that leads to enzyme conform-
ational change and increases entropy value. AChE is
mainly present in the central nervous system and its
principle role is to catalyze the hydrolysis of the neuro-
transmitter acetylcholine (ACh) to choline. This process
can return an activated cholinergic neuron back to its
resting state. The pathogenesis of AD is linked to aFigure 2 Inhibitory effect percentage of Berberine chloride and
Berberis vulgaris toward AChE.deficiency in the brain ACh [32]. Thus, AChE is an im-
portant pathogenic factor of AD and most pharmaco-
logical studies for screening agent to combat AD has
been focused on AChE inhibitors to alleviate cholinergic
deficit and improve neurotransmission [43].
B. vulgaris inhibited α-glucosidase enzyme activity
provides an effective way for diabetes treatment. The in-
hibition of α -glucosidase activity is one of therapeutic
approaches for reducing postprandial hyperglycemia. α-
Glucosidase inhibitor is effective in delaying absorption
of carbohydrates and suppressing postprandial hypergly-
cemia which contribute to the decrease in hemoglobin
A1C (HbA1c). The decreasing of HbA1c could reduce
the incidence of chronic vascular complication in dia-
betic patients [44].Figure 3 Inhibitory effect percentage of Berberine chloride and
berberis vulgaris toward glucosidase.
Table 4 Effect of berberine chloride and berberis on cellular prooxidants/antioxidants status
mg/rn Tears DPPH NO Gpx SOD
1
Extract Berberine Extract Berberine Extract Berberine Extract Berberine Extract Berberine
0 12 ± 2.5 22 ± 5.1 60 ± 12 0.3 ± 0.02 2.5 ± 0.2
0.2 9 ± 0.3 8 ± 0.7 19 ± 2.1 19 ± 0.1 50 ± 1.1 55 ± 1 0.33 ± 0.0 1 0.39 ± 0.0 5 3.9 ± 0.1 4 ± 0.3
0.4 7 ± 0.7 6 ± 0.1 17.1.1 16 ± 0.1 50 ± 2.1 53 ± 2.1 0.38 ± 0.0 3 0.42 ± 0.0 3 5 ± 0.3 5.1 ± 0.5
0.6 4.5 ± 0.4 5.3 ± 0.6 15 ± 0.9 14 ± 0.3 48 ± 1.9 49 ± 0.2 0.43 ± 0.0 2 0.48 ± 0.0 2 6.6 ± 0.2 6 ± 0.6
0.8 4.4 ± 0.8 4.5 ± 0.3 12.3 ± 0.5 12 ± 1.1 46 ± 2 46 ± 0.2 0.49 ± 0.0 2 0.52 ± 0,0 1 8.9 ± 0.4 9 ± 0.4
1 4 ± 1.1 4 ± 0.6 12 ± 2.3 11 ± 1.6 45 ± 9 43 ± 8.1 0.5 ± 0.05 0.55 ± 0.0 5 9.2 ± 0.9 10 ± 0.5
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GPx activities give a complete picture about the total an-
tioxidants capacity of the B. vulgaris ethanolic extracts.
It is important to determine the relative antioxidant cap-
acity of the extract since free radicals and oxidants in
the body commonly cause damage to aqueous-based cel-
lular structures and organelles as well as lead to peroxi-
dation of lipids [45]. Berberis vulgaris ethanolic extract
was a potent inhibitor for hepatocytes' lipid peroxidation
induced by Fe2+ and H2O2. This finding was proved pre-
viously on acidic and methanolic barberry extracts [1],
where berberine and barberry crude extract showed a
significant reductive ability and radicals scavenging ef-
fects, especially on hydroxyl and DPPH radicals. Also,
they have the ability to increase SOD and GPx activities.
It is reported that the most polar solvent dissolving sev-
eral compounds of different polarities such as acids,
sugars or glycosides which may be contributed to the
total phenolic content of the extract and represented
the highly antioxidant properties. Depending on this we
speculated that acetic acid extract preparationsFigure 4 Effect of different concentrations of Berberine chloride (Bi) a
peripheral blood mono nuclear cells (PBMC) at 24, 48 and 72 hrs. Datexhibited appreciable antioxidantive activity against the
generation of cellular oxidized lipid particles [1].
Nitric oxide is an essential bioregulatory molecule
required for several physiological processes like neural
signal transmission, immune response, control vaso-
dilatation and control of blood pressure. However, the
elevation of the NO results in several pathological
conditions, including cancer [46]. The plant/plant
products may have the property to counteract the ef-
fect of NO formation and in turn may be of consider-
able interest in preventing the ill effects of excessive
NO generation in vivo [46] B. vulgaris extract re-
duced the generation of NO in vitro in a concentra-
tion dependent manner. The implications of these
findings may be very important for human health,
since this herb has been used in several countries
from ancient times. Further, the high scavenging ac-
tivity may also help to arrest the chain of reactions
initiated by excess generation of NO, that are detri-
mental to the human health as excess NO is known
to damage the immune system.nd Berberis vulgaris extract (ex) on proliferation of normal
a were represented as stimulation index (SI).
Figure 5 Effect of Berberine chloride (Bi) and Berberis vulgaris extract (ex) on viability of three human cancer cell lines. Different
concentration of both Berberine chloride and berberis vulgaris were incubated with 105 cells /ml of breast cancer (MCF7), Liver Cancer (HepG2)
and Colon cancer (CACO-2) cell lines (ATTC, see Methods) for 24, 48 and 72 hours, cell viability were evaluated by using neutral red cell stainig.
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http://www.biomedcentral.com/1472-6882/13/218Chemotherapeutic drugs generally have low safety des-
pite of their high efficacy. This might be due to toxicity
and side effects that are usually associated with almost
all types of chemotherapeutic medicine, besides the gen-
erated resistance to this group of therapeutic drugs
which makes it more difficult to the patients. Between
1982 and 2002, more than half of the new anti-cancer
chemical compounds were derived directly or indirectly
from natural resources either microorganisms, plant or
both [47,48]. Berberine as an isoquinoline alkaloid iso-
lated from different types of plants is well recognized for
its assorted pharmacological actions, for exampleTable 5 Inhibition concentrations of both Berberine
chloride and Berberis vulgaris that can inhibit the growth




24 48 72 24 48 72
PBMC 0.66649 5.568 883 .994 0.90 19 6.05 1 2.546
MCF7 0.01593 0.00443 0.00195 0.01561 0.00454 0.00397
Rep 02 0.06586 0.0 1149 0.00 173 0.06805 0.00555 0.00408
CAC 0-2 0.0 1764 0.005 1 0.00 183 0.04996 0.00384 0.00 144berberine purified from Coptidis Rhizoma (Huanglian) is
used in Chinese medicine for heat dissipation and de-
toxification [49], moreover, berberine purified from
members of family
Berberidaceae is well known for its anti-inflammatory
and immunosuppressive capacity beside other pharma-
cological activities [50-56]. Berberine is also recognized
for its anti-cancer activity [56-64]. For assessment of an-
ticancer effect of certain compounds, cytotoxicity on pri-
mary normal cell culture must be formed to calculate
the safe dose. Several types of primary cells can be used;
one of them is PBMC [65]. Furthermore, we based on
neutral red assay for cytotoxicity study as it is reported
that neutral red and the MTT assay being the most
sensitive in detecting cytotoxic events compared to the
LDH leakage and the protein assay [66]. Moreover, it is
well known that berberine shifted the balance between
Th2 and Th1, increased the production of IL 12 and al-
tered the cytokines profile [67]. So, it mimics PHA re-
sponse and in such cases PHA did not used to make
cell stimulation because it could cause cell death due to
cell overstimulation [68,69].
In the present study, the anti-cancer activity of berber-
ine chloride and total ethanolic extract from B. vulgaris
was examined, in which this herb as member of the
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its anti-cancer activity. At first, the dose for this in vitro
testing was determined using healthy PBMC, and as in-
dicated in Figure 3, for berberine chloride and B.
vulgaris ethanolic extracts, both are slightly stimulate
immune cells and the safety margin concentrations of
both berberine chloride and B. vulgaris ethanolic ex-
tracts are significantly high (IC50 =0.66649, 5.568 and
883.994 mg/ml after incubation at 24, 48 and 72 hours).
Followed by examining the effect of 1, 5, 10, 50 and
100 μg/ml of both berberine chloride and b. vulgaris ex-
tracts on viability of breast, hepatic, colon and cervix
cancer cell lines after incubation for 24, 48, and 72 hours.
The cell viability of all cancer cell line used in this study
was decreased significantly and in a dose dependent
manner with both berberine chloride and berberis
vulgaris ethanolic extracts (Figure 5 and Table 4). This
data are in agreement with the published data about
other members of family berberidaceae [56,58-60,64].
The mode of action of both berberine chloride and
b. vulgaris ethanolic extracts were not determined dur-
ing the course of the present study, but in another study
performed in our laboratory (data not shown) that p53
expression was increased due to treatment with both
berberine chloride and b. vulgaris ethanolic extracts.
This might explain that b. vulgaris ethanolic extract can
induce cancer cell death (apoptosis) through this mode
of action. On the other hand, the antioxidant activity
might play a major role in increasing efficiency of such
extracts to kill cancer cells and protect normal cells.Conclusion
This work demonstrates the potential of the bioactive in-
gredients of barberry on suppressing lipid peroxidation,
suggesting a promising use in the treatment of hepatic
oxidative stress, Alzheimer and idiopathic male factor
infertility. Besides, berberis vulgaris ethanolic extract can
induce cancer cell death that could return to its power-
ful antioxidant activity. Although the significant cura-
tive potential of b. vulgaris against many diseases, it
didn’t deposited in a publicly available herbarium yet.
Thus, for further experimental investigations, protocol
for ingredients’ extraction mentioned in methods sec-
tion is recommended to be followed. Furthermore, the
plant has been registered in several herbarium and we
use this as reference, also we purchased the root from
USA market so how come we register it in our herbar-
ium as it is not grown in Egypt but we will register the
extract after we finish complete toxicological study
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